Teradek Unveils Bolt Wireless SDI Transmitter for Video Professionals
Company introduces its first product delivering zero delay uncompressed video
Teradek, the world leader in compact HD H.264 video encoders and accompanying transmission systems, today announced the Teradek Bolt™, the newest addition to their award-winning line of wireless video transmission systems. Bolt is a Wireless SDI Pro™ transmitter and receiver set that transmits zero delay uncompressed HD video at full 1080p60 4:2:2 fidelity.
"We’re very excited about the potential Bolt brings to large and small productions alike," said Nicol Verheem, CEO of Teradek. “While our Cube encoder is very popular and changed the landscape for video assist and Internet streaming, there has always been a small niche that we didn't serve; those that truly need zero delay systems such as the 1st ACs. We designed Bolt to be the most compact and affordable zero latency HD-SDI transmitter available so that users can benefit from untethered shooting of up to 300 feet.”
Bolt is made up of a compact milled T6061 aluminum transmitter and an equally small receiver made of durable ABS plastic. The transmitter comes with a 3G-SDI input, an HD-SDI loop-through, numerous 1/4" 20 holes for mounting, internal Li-Ion battery, and a Lemo DC input for long term power from any 6-18V battery or DC supply. The receiver offers dual 3G-SDI outputs, allowing simultaneous monitoring as well as connecting to other Teradek systems.
Bolt can transmit uncompressed full HD video at up to 300ft and can coexist with other wireless networks by dynamically adjusting the frequency bands used in real time. Each transmitter can feed video to up to 256 receivers simultaneously without any degradation in video quality. Users can output the video from a Bolt receiver into a Teradek Cube for additional workflow enhancements such as proxy recording, Internet streaming, and monitoring on iPads and iPhones.
Bolt is expected to ship in early Q4 2012 for $1,990 and will be showcased along with the Company’s other products at the International Broadcasting Convention (IBC), from September 7-11, 2012 at Stand 9.C25.
ABOUT TERADEK
Teradek is a leader in compact HD H.264 codecs and IP transmission systems used in filmmaking, live video production, and broadcast television. Teradek's Cube is the world’s best selling miniature HD encoder, and transmits 1080p video over Ethernet, WiFi or cellular networks to iPads, CDNs, or IPTV decoders. For more information, visit http://www.teradek.com .
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50397170&lang=en
Contact:
Teradek
Michael Gailing
+1-949-743-5774
mike@teradek.com
or
For
Teradek
Stacey Hurwitz
+1-408-472-4120
stacey.hurwitz@teradek.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t
Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a
Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release
Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom